-
28 April 2025 23:07:03
- Source: Sharecast
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
LONDON AND PHILADELPHIA - April 28, 2025, Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Avacta Group plc |
|||
|
Name of scheme: |
EMI scheme |
|||
|
Period of return: |
From: |
28 October 2024 |
|
27 April 2025 |
|
Balance of unallotted securities under scheme(s) from previous return: |
275,380 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
47,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
228,380 |
|||
|
|
|
|
|
|
|
Name of applicant: |
Avacta Group plc |
||||
|
Name of scheme: |
LTIP/ESOS scheme |
||||
|
Period of return: |
From: |
28 October 2024 |
|
27 April 2025 |
|
|
Balance of unallotted securities under scheme(s): |
5,913,257 |
||||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
||||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
4,366,882 |
||||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
1,546,375 |
||||
|
|
|
|
|
|
|
|
|
|
||||
|
Name of contact: |
Brian Hahn, Company Secretary |
||||
|
Telephone number of contact: |
+ 44 (0) 1904 217070 |
||||
Ends-
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Michael Vinegrad, Group Communications Director |
https://avacta.com/ |
|
|
|
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
|
www.peelhunt.com
|
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers
ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
www.panmureliberum.com
avacta@icrhealthcare.com
|
|
Investor Contact Renee Leck THRUST Strategic Communications
|
renee@thrustsc.com
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
Carly@carlyscadutoconsulting.com |
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.